Huoxue Jiedu Formulas (活血解毒方药) as an Adjunctive Therapy for Patients with Binding of Stasis and Toxin Syndrome during the Vulnerable Period after Myocardial Infarction:A Prospective Real-World Study
|更新时间:2025-12-04
|
Huoxue Jiedu Formulas (活血解毒方药) as an Adjunctive Therapy for Patients with Binding of Stasis and Toxin Syndrome during the Vulnerable Period after Myocardial Infarction:A Prospective Real-World Study
Journal of Traditional Chinese MedicineVol. 66, Issue 23, Pages: 2467-2474(2025)
GENG Xiaofei,YANG Yingxi,YAN Zhipeng,et al.Huoxue Jiedu Formulas (活血解毒方药) as an Adjunctive Therapy for Patients with Binding of Stasis and Toxin Syndrome during the Vulnerable Period after Myocardial Infarction:A Prospective Real-World Study[J].Journal of Traditional Chinese Medicine,2025,66(23):2467-2474.
GENG Xiaofei,YANG Yingxi,YAN Zhipeng,et al.Huoxue Jiedu Formulas (活血解毒方药) as an Adjunctive Therapy for Patients with Binding of Stasis and Toxin Syndrome during the Vulnerable Period after Myocardial Infarction:A Prospective Real-World Study[J].Journal of Traditional Chinese Medicine,2025,66(23):2467-2474.DOI: 10.13288/j.11-2166/r.2025.23.013.
Huoxue Jiedu Formulas (活血解毒方药) as an Adjunctive Therapy for Patients with Binding of Stasis and Toxin Syndrome during the Vulnerable Period after Myocardial Infarction:A Prospective Real-World Study
(活血解毒方药, HJF) as an adjunctive treatement for patients with binding of stasis and toxin syndrome during the vulnerable period after acute myocardial infarction (AMI) percutaneous coronary intervention (PCI) surgery, and to explore its potential mechanism from the perspective of serum neutrophil extracellular traps (NETs).
Methods
2
A total of 129 patients with binding of stasis and toxin syndrome within 6 months after PCI for AMI were enrolled and divided into a treatment group (65 cases) and a control group (64 cases) based on patients' willingness to take Chinese herbal medicine. The control group received standard western medical therapy alone, while the treatment group additionally received HJF, one dose daily. Both groups were treated for four weeks. Before and after treatment, TCM syndrome scores were assessed. Seattle angina questionnaire (SAQ) was used to record angina stability and frequency scores, while the short form-36 health survey (SF-36) was employed to assess quality of life across eight dimensions, including physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The Pittsburgh sleep quality index (PSQI) was used to evaluate sleep quality, and the patient health questionnaire-15 (PHQ-15) was used to assess psychosomatic symptoms; Duke activity status index (DASI) was used to measure daily physical activity. Serum levels of neutrophil extracellular traps (NET) markers including myeloperoxidase-DNA (MPO-DNA), neutrophil elastase-DNA (NE-DNA), and citrullinated histone H3 (CitH3) were measured in 20 patients from the treatment group.
Results
2
After treatment, TCM syndrome score, PSQI score and PHQ-15 score in both groups significantly decreased, while DASI score, angina stability and frequency scores, and all eight dimensions of the SF-36 scale significantly increased (
P
<0.05). Compared to the control group, the treatment group had significantly lower TCM syndrome scores and significantly higher DASI, angina stability and frequency scores (
P
<0.05), as well as higher scores in the SF-36 dimensions of physical functioning, role-physical, social functioning, bodily pain, and vitality (
P
<0.05). After treatment, serum levels of MPO-DNA, CitH3, and NE-DNA in the treatment group were significantly reduced (
P
<0.05).
Conclusion
2
HJF combined with conventional therapy can significantly improve angina symptoms, TCM syndrome scores, and psychosomatic conditions in patients with binding of stasis and toxin syndrome during the vulnerable period after AMI. It also enhances quality of life, sleep quality, and daily physical activity. The underlying mechanism may be associated with the inhibition of serum NETs level.
SONG J , MURUGIAH K , HU S , et al . Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China [J]. Heart , 2020 , 107 ( 4 ): 313 - 318 .
UEDA Y , ASAKURA M , YAMAGUCHI O , et al . The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up [J]. J Am Coll Cardiol , 2001 , 38 ( 7 ): 1916 - 1922 .
ARNOLD N , KOENIG W . Lipid lowering drugs in acute coronary syndromes (ACS) [J]. Curr Atheroscler Rep , 2023 , 25 ( 12 ): 939 - 946 .
LI YW , CHEN SX , YANG Y , et al . Colchicine inhibits NETs and alleviates cardiac remodeling after acute myocardial infarction [J]. Cardiovasc Drugs Ther , 2024 , 38 ( 1 ): 31 - 41 .
KNUUTI J , WIJNS W , SARASTE A , et al . 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes [J]. Eur Heart J , 2020 , 41 ( 3 ): 407 - 477 .
THOMAS M , JONES PG , ARNOLD SV , et al . Interpretation of the Seattle angina questionnaire as an outcome measure in clinical trials and clinical care: a review [J]. JAMA Cardiol , 2021 , 6 ( 5 ): 593 - 599 .
BRAZIER JE , HARPER R , JONES NM , et al . Validating the SF-36 health survey questionnaire: new outcome measure for primary care [J]. BMJ , 1992 , 305 ( 6846 ): 160 - 164 .
CHONG B , JAYABASKARAN J , JAUHARI SM , et al . Global burden of cardiovascular diseases: projections from 2025 to 2050 [J]. Eur J Prev Cardiol , 2025 , 32 ( 11 ): 1001 - 1015 .
Effect of Yiqi Liangxue Shengji Formula (益气凉血生肌方) on Recurrence of Angina Pectoris and Quality of Life after Percutaneous Coronary Intervention in Coronary Heart Disease Patients with Qi Deficiency and Blood Stasis Syndrome and Binding of Stasis and Heat Syndrome: A Randomized, Triple-blind, Placebo-controlled Parallel Trial
Effect of Heat-sensitive Moxibustion on Quality of Life and Immune Function in Non-Small Cell Lung Cancer Patients with Qi Deficiency and Phlegm Stasis Syndrome Undergoing Chemotherapy:A Randomized Controlled Trial
Effect of Optimized New Shengmai Powder (优化新生脉散方) on Exercise Tolerance in Patients with Chronic Heart Failure of Qi Deficiency,Blood Stasis and Fluid Retention Syndrome:A Randomized,Double-Blind,Placebo-Controlled Trial
Effectiveness Evaluation of Exhalation-Inhalation Exercise on Early Pulmonary Rehabilitation for Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Effect of Yang-Reinforcing and Blood-Activating Therapy on the Long-Term Prognosis for Dilated Cardio-myopathy Patients with Yang Deficiency and Blood Stasis Syndrome:A Retrospective Cohort Study
Related Author
WANG Wujiao
YANG Zhifei
LI Yuxuan
GUO Lingli
WU Yuze
LIN Qian
WAN Jie
ZHAN Wenhao
Related Institution
Beijing University of Chinese Medicine
Dongzhimen Hospital,Beijing University of Chinese Medicine
Dongfang Hospital,Beijing University of Chinese Medicine
Guangdong Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Guangzhou University of Chinese Medicine
Jinan Vocational College of Nurisng,Shandong Pronvince